Beta

Novabridge biosciencesNBP.US Overview

US StockHealthcare
(No presentation for NBP)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

NBP AI Insights

NBP Overall Performance

NBP AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

NBP Recent Performance

-1.65%

Novabridge biosciences

-1.10%

Avg of Sector

-0.49%

S&P500

NBP PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check NBP's Trend

NBP Key Information

NBP Valuation Metrics

NBP Profile

Price of NBP

NBP FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

NBP Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.92
PE Ratio (TTM)
-
Forward PE
2.68
PS Ratio (TTM)
25.39
PB Ratio
1.23
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.92
PE Ratio (TTM)
-
Forward PE
2.68
PS Ratio (TTM)
25.39
PB Ratio
1.23
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is NBP's latest earnings report released?

    The most recent financial report for Novabridge biosciences (NBP) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating NBP's short-term business performance and financial health. For the latest updates on NBP's earnings releases, visit this page regularly.

  • How much debt does NBP have?

    As of the end of the reporting period, Novabridge biosciences (NBP) had total debt of 3.07M, with a debt ratio of 0.01. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does NBP have?

    At the end of the period, Novabridge biosciences (NBP) held Total Cash and Cash Equivalents of 210.63M, accounting for 0.81 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is NBP's EPS continuing to grow?

    According to the past four quarterly reports, Novabridge biosciences (NBP)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What are the PEG ratio and PE ratio of NBP?

    The latest valuation data shows Novabridge biosciences (NBP) has a Price-To-Earnings (PE) ratio of -6.18 and a Price/Earnings-To-Growth (PEG) ratio of -0.35. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.